Colin Carrie on Questions on the Order Paper

With regard to Health Canada’s approval of mRNA vaccine products: (a) can Health Canada definitively exclude the possibility that undesirable effects to human cells and tissues (e.g. cell proliferation, toxicity) may be caused by conceivable mechanisms of action, such as (i) the creation of aberrant proteins by means of ribosomal frameshifting, (ii) the concomitant injection of residual DNA plasmid fragments, which, according to Speicher et al., are known to exceed by 188 to 509 fold the guideline limits for residual DNA that the United States Food and Drug Administration and the World Health Organization set at 10 ng/dose when measured by fluorometry, and the subsequent transfection of these fragments into the cell’s nucleus with the help of the lipid nanoparticles (LNPs), (iii) the concomitant injection of other contaminants such as double-stranded RNA or fragmented RNA, (iv) the presence of abnormally high levels of IgG4 antibodies due to repeated vaccination, (v) the concomitant injection of bacterial endotoxins previously detected in Pfizer and Moderna vials, which may also be transfected via LNPs, (vi) the potential for reverse transcriptase of mRNA into DNA, (vii) the presence of SV40 promoter/enhancer DNA as an additional contaminant that could transfect the cell and integrate into the genome, (viii) the LNP-facilitated entry of mRNA and spike protein across the blood-brain barrier, across the placenta, into breast milk, and into organs and tissues, particularly of the heart, bone marrow and brain; (b) when considering the mechanisms of action in (a), can Health Canada definitively exclude the possibility that any combination of two or more of these mechanisms may cause undesirable effects of cell proliferation or toxicity; (c) has Health Canada completed a risk-benefit assessment in relation to (i) each of these singular mechanisms of action, (ii) the combination of any of the mechanisms listed in (a); (d) if the answer to (c) is affirmative, what is the risk-benefit assessment; (e) if the answer to (c) is negative, why has Health Canada not completed a risk-benefit assessment; and (f) did Health Canada set new safety limits for levels of residual DNA in the presence of a lipid nanoparticle delivery system in an mRNA vaccine product?